Advanced search×

Is there a place for drug combination strategies using clinical pharmacology attributes?--review of current trends in research.

Audio, Transactions of the IRE Professional... 4(3):220-8 (2009) PMID 19500074

Drug discovery is the main flag ship of the pharmaceutical industry in order to ensure that innovations constantly occur in the identification and development of novel therapeutic options for the management of diseases. Recently, research trends that take advantage of the safety and efficacy of marketed products by combining such products with other agents to influence certain clinical pharmacology attribute(s) have emerged. The focus of the review is to evaluate ongoing research trends that have considered leveraging on certain clinical pharmacology attributes in the areas of viral infection (HIV and influenza) and oncology. Case studies discussed in this review include: a) the use of probenecid to block the organic anion renal transport of oseltamivir carboxylate (a key active metabolite of oseltamivir phosphate) to reduce the oral dose of oseltamivir phosphate; b) the use of rifampicin to induce the CYP2C19 enzyme and thereby, promote the formation of a potent active metabolite M8 (nelfinavir hydroxyl-t-butylamide) and achieve sustained blood levels to combat HIV infection along with ritonavir; c) the use of CYP3A4 inhibitors such as ketoconazole, cyclosporin A, ritonavir etc to overcome the extensive presystemic metabolism of docetaxel and enhance the oral bioavailability of docetaxel. Along with the case studies, several hurdles for drug development such as dose selection, frequency of dosing, and duration of the clinical studies, picking the right surrogate(s) for efficacy, evaluation of drug-drug interaction potential with other co-substrates have been discussed in line with the current day requirements for a sound clinical and regulatory strategy. In summary, based on the collated information, a pragmatic approach would render feasibility for a balanced therapy management using combined clinical pharmacology attributes of drugs.

Version: za2963e q8za6 q8zb1 q8zca q8zdc q8ze6 q8zf2 q8zg3

Similar articles you may find interesting…

  1. Three feasible strategies to minimize kidney injury in 'incipient AKI'

    Nat Rev Nephrol (2013) PMID 23649020

    We propose three strategies to preserve kidney function and minimize further kidney injury in patients with 'incipient AKI'. These include-when appropriate for the prevailing cause of 'incipient AKI'-use of low-chloride-containing intravenous solutions, continued use of renin-angiotensin system anta...
  2. Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination.

    Malar J 12(1):153 (2013) PMID 23647969

    The use of ivermectin solves many challenges identified for future vector control strategies. It is an effective and safe endectocide that was approved for human use more than 25 years ago. Recent studies suggest it might become an effective and complementary strategy in malaria elimination and erad...
  3. Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid Leukemia-a wise liaison?

    Leukemia (2013) PMID 23644421

    Treatment options for older patients with advanced myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) are limited and the prognosis remains poor, thereby warranting development of novel therapies. Aberrant epigenetic modifications, including altered DNA methylation, seem...